Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lamotrigine for Neuroprotection in Secondary Progressive MS
NCT00257855Phase 2Completed
- Sponsor
- UCLH
- Start
- Nov 2005
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in secondary-progressive multiple sclerosis (SPMS) comparing Lamotrigine with Placebo (2 arms). Primary endpoint: Change in central brain volume on MRI using the 'Loseff method' at 24 months. Started Nov 2005; status: completed.
02
Drugs
lamotrigine
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT00257855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00257855.